Leukemia & Lymphoma最新文献_第2页

Diagnostic utility of plasma circulating tumor DNA (ctDNA) in primary large B-cell lymphoma of the central nervous system (PCNS-LBCL): A paradigm shift? 血浆循环肿瘤DNA （ctDNA）在原发性中枢神经系统大b细胞淋巴瘤（PCNS-LBCL）中的诊断价值：范式转变？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-23 DOI: 10.1080/10428194.2025.2508298

Andrei Bucaloiu, Pouya Jamshidi, Karan Dixit, Madina Sukhanova, Hamza Tariq

引用次数: 0

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. 皮下单药治疗日本复发或难治性滤泡性淋巴瘤患者：EPCORE NHL-3试验的主要结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-07-09 DOI: 10.1080/10428194.2025.2525983

Koji Izutsu, Daigo Akahane, Tomomi Toubai, Toko Saito, Yuko Mishima, Tomoaki Fujisaki, Momoko Nishikori, Takahiro Kumode, Youko Suehiro, Kenji Ishitsuka, Rebekah Conlon, Ami Takahashi, Barbara D'Angelo Månsson, Elena Favaro, Noriko Fukuhara

{"title":"Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.","authors":"Koji Izutsu, Daigo Akahane, Tomomi Toubai, Toko Saito, Yuko Mishima, Tomoaki Fujisaki, Momoko Nishikori, Takahiro Kumode, Youko Suehiro, Kenji Ishitsuka, Rebekah Conlon, Ami Takahashi, Barbara D'Angelo Månsson, Elena Favaro, Noriko Fukuhara","doi":"10.1080/10428194.2025.2525983","DOIUrl":"10.1080/10428194.2025.2525983","url":null,"abstract":"An unmet need exists for patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose disease remains incurable. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for R/R FL and different types of R/R large B-cell lymphoma after ≥2 prior lines of therapy (pLOT) in the US, Europe, and Japan. Regional data are critical to contextualize global trial data. In the Japan-specific EPCORE NHL-3 trial (phase 1/2), 21 adults with R/R FL and ≥2 pLOT received subcutaneous epcoritamab (two step-up doses, then 48-mg full doses) until progression. Median follow-up was 21.2 months. Responses were frequent and deep (overall response rate, 95.2%; complete response rate, 76.2%), including in high-risk subgroups, as well as durable. Safety was manageable; cytokine release syndrome events had predictable timing and were mostly low grade, and no fatal treatment-emergent adverse events occurred. These results support epcoritamab as a new treatment option for Japanese patients with R/R FL.Clinical trial registration numbers: NCT04542824; JapicCTI-205408; jRCT2080225312.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1913-1921"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression of disease within 6 months: revised early disease progression threshold for ENKTL. 6个月内疾病进展：修订ENKTL的早期疾病进展阈值。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-11 DOI: 10.1080/10428194.2025.2516257

Miao Zhong, Hailing Liu, Renfu Gui, Jing Zhang, Sanmei Wang, Yi Miao, Chongyang Ding, Lvwen Chen, Yuxiao Zhao, Xiran Wang, Xiaoyan Qu, Zhengxu Sun, Ran Li, Jianyong Li, Lei Cao, Lei Fan

引用次数: 0

Lymphoma: factors associated with unplanned diagnostic pathways and survival -a nationwide Danish register-based cohort study. 淋巴瘤：与非计划诊断途径和生存相关的因素——丹麦全国基于登记的队列研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-27 DOI: 10.1080/10428194.2025.2508299

Linda Aagaard Rasmussen, Peter Vedsted, Henry Jensen, Henrik Frederiksen, Tarec Christoffer El-Galaly, Peter de Nully Brown, Line Flytkjær Virgilsen

{"title":"Lymphoma: factors associated with unplanned diagnostic pathways and survival -a nationwide Danish register-based cohort study.","authors":"Linda Aagaard Rasmussen, Peter Vedsted, Henry Jensen, Henrik Frederiksen, Tarec Christoffer El-Galaly, Peter de Nully Brown, Line Flytkjær Virgilsen","doi":"10.1080/10428194.2025.2508299","DOIUrl":"10.1080/10428194.2025.2508299","url":null,"abstract":"The objective was to investigate how patient characteristics, clinical characteristics and prognosis were associated with lymphoma diagnoses in unplanned pathways. We included 7,157 consecutive patients diagnosed with lymphoma in a nationwide register-based study in Denmark. An unplanned pathway was defined as an acute admission within 30 days before diagnosis and compared to all other pathways combined. A total of 21% of patients were diagnosed in unplanned pathways, varying from 13% in indolent non-Hodgkin lymphoma to 32% in aggressive non-Hodgkin lymphoma. The probability of being diagnosed in an unplanned pathway was higher for patients with comorbidity, B-symptoms, abnormal blood test results, advanced disease stage and poor performance score (PS) at diagnosis. Diagnosis in an unplanned pathway was associated with higher mortality, for example, HR 2.03 (95% CI:1.74-2.38 for PS 0). Increased disease severity at diagnosis was associated with unplanned diagnostic pathways. Diagnosis in an unplanned pathway was associated with higher mortality.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1863-1874"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation. 氟达拉滨剂量对造血干细胞移植移植相关结果的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-11 DOI: 10.1080/10428194.2025.2509701

Ana Maria Meireles, Ana Carolina Dominguesde Oliveira Rodrigues Amarante, Beatriz Mota Coelho Marques Catita, Maria Teresa Pegado Barroso Abilheira Monjardino, Pedro Martinho Gonçalves de Abreu Gouveia, Cláudia Sílvia da Rocha Moreira, Luís Cláudiode Jesus Leite, Rita Coutinho, Rosa Branca Santos Ferreira, Gil Paiva Brás, Manuel Guerreiro, Carlos Pinho Vaz, José Mário Mariz

引用次数: 0

Outcomes of respiratory syncytial virus infection among hospitalized adults with hematological malignancies. 血液系统恶性肿瘤住院成人呼吸道合胞病毒感染的结局。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-29 DOI: 10.1080/10428194.2025.2512030

Nikhil Vojjala, Lakshmi Kattamuri, Ritwik Dey, Rishab Prabhu, Aditi Sharma, Kunal Sharma, Geetha Krishnamoorthy, Vijendra Singh

引用次数: 0

Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML). 急性髓性白血病（AML）患者诱导治疗后白细胞动力学对预后的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-02 DOI: 10.1080/10428194.2025.2512029

Jesamine Jany, Jan-Henrik Mikesch, Klaus Wethmar, David Baden, Irina Osiaevi, Georg Lenz, Christoph Schliemann, Alexander Pohlmann

{"title":"Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).","authors":"Jesamine Jany, Jan-Henrik Mikesch, Klaus Wethmar, David Baden, Irina Osiaevi, Georg Lenz, Christoph Schliemann, Alexander Pohlmann","doi":"10.1080/10428194.2025.2512029","DOIUrl":"10.1080/10428194.2025.2512029","url":null,"abstract":"Acute myeloid leukemia (AML) is associated with broadly varying white blood cell (WBC) counts at the time of diagnosis and treatment. This study examined the association of WBC kinetics and outcome in 443 patients of '7 + 3' intensively treated AML patients, differentiating between leukocytosis and non-leukocytosis. WBC kinetics like WBC nadir, area under the curve (AUC) and negative slope were assessed by regression analyses adjusted for known risk factors. Leukocytosis was associated with inferior overall survival (OS: HR 1.369; 95% CI 1.066 - 1.759; p = 0.013), event-free survival (EFS: HR 1.286; 95% CI 1.035 - 1.599; p = 0.013) and increased early death (ED: p < 0.001) compared to the non-leukocytosis cohort. In patients with leukocytosis - regression analyses identified higher WBC nadir and higher AUC as predictors of worse outcome (WBC: HR 1.176; 95% CI 1.03-1.342; p = 0.017 and AUC: HR 1.001; 95% CI 1-1.003; p = 0.039). In contrary, non-leukocytosis patients presented an even shorter OS the lower their WBC nadir (HR 3.356; 95% CI 1.332 - 8.475; p = 0.01) and AUC dropped during induction (HR 1.019; 95% CI 1.001 - 1.040; p = 0.041). Multivariate analyses largely confirmed these effects.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1809-1820"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old. calgb10403与HyperCVAD治疗≥40岁成人费城染色体阴性急性淋巴细胞白血病的比较

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-21 DOI: 10.1080/10428194.2025.2506003

Purav Mehta, Dat Ngo, Jose Tinajero, Vaibhav Agrawal, Paul Koller, Hoda Pourhassan, Shukaib Arslan, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss

引用次数: 0

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm. olutasidenib与ivosidenib在复发或对venetoclax难治的异柠檬酸脱氢酶1突变急性髓系白血病患者中的有效性：2102-HEM-101试验与基于美国电子健康记录的外部对照组

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-13 DOI: 10.1080/10428194.2025.2514894

Catherine E Lai, Thomas P Leahy, Alex J Turner, Amber Thomassen, Lixia Wang, Aaron D Sheppard, Jorge Cortes

{"title":"Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.","authors":"Catherine E Lai, Thomas P Leahy, Alex J Turner, Amber Thomassen, Lixia Wang, Aaron D Sheppard, Jorge Cortes","doi":"10.1080/10428194.2025.2514894","DOIUrl":"10.1080/10428194.2025.2514894","url":null,"abstract":"First-line venetoclax (VEN) treatment for acute myeloid leukemia (AML) has high relapse rates, with limited evidence guiding subsequent therapy sequencing. This study evaluated the effectiveness of olutasidenib (OLU) versus ivosidenib (IVO) for patients withIDH1 relapsed/refractory (R/R) AML previously treated with VEN based therapy. Outcomes were compared between a subcohort of OLU-treated patients from the 2102-HEM-101 trial and an external control arm of IVO-treated patients from the Loopback Analytics electronic health record database. Entropy balancing was applied to align key prognostic variables. Risk differences (RD) for response/TI were estimated via logistic regression, and hazard ratios (HR) for OS via Cox regression. Following weighting, treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). Results suggest favorable effectiveness of OLU versus IVO in this population.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1821-1832"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada. 在加拿大，使用嵌合抗原受体t细胞治疗的患者的实际医疗保健费用。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-17 DOI: 10.1080/10428194.2025.2518440

Lisa Masucci, John Kuruvilla, Beate Sander, Anca Prica, William W L Wong, Kelvin K W Chan

引用次数: 0